

Idiopathic Pulmonary Fibrosis Systemic Sclerosis With Lung Involvement

**A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease**

**Trial Status**  
Recruiting

**Trial Runs In**  
17 Countries

**Trial Identifier**  
NCT05785624 2022-502828-42  
GB44496

*The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.*

***Trial Summary:***

The main purpose of the study is to evaluate the efficacy of vixarelimab compared with placebo on lung function in participants with idiopathic pulmonary fibrosis (IPF) and in participants with systemic sclerosis-associated interstitial lung disease (SSc-ILD). Participants who complete 52-weeks of treatment in the Double-blind Treatment (DBT) period can choose to enroll in the optional Open-label Extension (OLE) period to receive treatment with vixarelimab for another 52 weeks.

**Genentech, Inc.**  
Sponsor

**Phase 2**  
Phase

**NCT05785624 2022-502828-42 GB44496**  
Trial Identifiers

***Eligibility Criteria:***

**Gender**  
All

**Age**  
≥18 Years & ≤ 85 Years

**Healthy Volunteers**  
No